American Society of Hematology (ASH)

The American Society of Hematology (ASH) is a professional organization representing hematologists. It was founded in 1958. Its annual meeting is held in December of every year and has attracted more than 30,000 attendees. The society publishes the medical journal Blood, the most cited peer-reviewed publication in the field, which is available weekly in print and online, as well as the newly launched, online, peer-reviewed open-access journal, Blood Advances.

Daratumumab plus Pomalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Results of a 4-Arm Phase 1b Study

ASH 2015 – Multiple Myeloma

Daratumumab in combination with pomalidomide and dexamethasone is being evaluated in a 4-arm, multicenter, phase 1b study in patients with at least 2 lines of prior therapy and relapsed or relapsed and refractory multiple myeloma. Initial findings show deep and durable responses, a high response rate, and good tolerability. Read More ›

Lenalidomide Maintenance in Patients with Relapsed DLBCL Who Cannot Be Treated with Consolidative Transplantation

ASH 2015 – Castleman's Disease, Lymphoma & CLL

Improving the Standard of Care

ASH 2015 – Multiple Myeloma

R. Donald Harvey believes that developing well-tolerated drugs is the key to improving the standard of care in managing patients with hematologic malignancies. Read More ›

Addition of Obinutuzumab or Rituximab to Chlorambucil in Treatment-Naive Patients with CLL: Updated Survival Analysis from the CLL11 Study

ASH 2015 – Castleman's Disease, Lymphoma & CLL

The Role of Patient Support Services

ASH 2015 – Multiple Myeloma

R. Donald Harvey stresses the importance of patient support services in addressing financial challenges and building support communities for both patients and their families. Read More ›

Impact of High-Risk Prognostic Parameters on Ibrutinib/Bendamustine/Rituximab versus Bendamustine/Rituximab Treatment Outcomes in Patients with Relapsed CLL/SLL: Results from the HELIOS Trial

ASH 2015 – Castleman's Disease, Lymphoma & CLL

Managing Patients on Oral Oncolytics

ASH 2015 – Multiple Myeloma

Ali McBride provides an overview of the role of the pharmacist and the importance of working with a broad team of healthcare providers in managing patients on oral oncolytics. Read More ›

ASH 2015 – Castleman's Disease, Lymphoma & CLL

Exciting Time for Treating Myeloma

ASH 2015 – Multiple Myeloma

R. Donald Harvey speaks about the addition of new medicines and how they can be included in the existing treatment armamentarium. Read More ›

American Society of Hematology (ASH)

Page 38 of 44